Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

However, some nerve fibers remained active and continued promoting cancer growth. To completely cut off nerve support, the ...

Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Funding from Cancer Prevention and Research Institute of Texas has brought more than 324 distinguished cancer researchers to Texas.

GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in refractory germ cell ...

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.